

16 April 2021

<b>To, Dy. General Manager Department of Corporate Services, BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai – 400 001</b>	<b>To, The Manager – Listing National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051</b>
<b>Ref: Scrip Code: 532296</b>	<b>Ref: Scrip Name: GLENMARK</b>

Dear Sirs,

**Re: Proposed Initial Public Offering (“IPO”) of Glenmark Life Sciences Limited- Filing of draft red herring prospectus**

We wish to inform you that Glenmark Life Sciences Limited, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, has today, i.e. on April 16, 2021, filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer, comprising of a fresh issue of up to ₹11,600 million and an offer for sale of up to 7,305,245 equity shares of ₹2 each of Glenmark Life Sciences Limited, by Glenmark Pharmaceuticals Limited (“Offer”).

In connection with the aforementioned Offer, the board of directors of Glenmark Pharmaceuticals Limited, at its meeting held today, i.e. April 16, 2021, accorded its approval for the offer for sale of up to 7,305,245 equity shares of ₹2, in the Offer.

The IPO will be subject to market conditions, receipt of applicable approvals and other considerations.

The above is for your information, records and dissemination.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**



Harish Kubler  
**Company Secretary and Compliance Officer**

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)